Tecentriq(atezolizumab)

[Drug name] Tecentriq
[Generic name]
[English name] atezolizumab
[Chinese pinyin]

[Function and indications] The first PD-L1 inhibitor approved by the FDA: for new targeted treatment of bladder cancer. The FDA also approved the Tecentriq auxiliary diagnostic reagent Ventana PD-L1 (SP142) analysis kit for measuring the expression level of PD-L1 in tumor-infiltrating immune cells.

[Model and specification] Injection: 1200 mg/20 mL (60 mg/mL) solution in a single-dose vial

[Usage and dosage] Dilute before intravenous infusion. Administer 1200 mg as an intravenous infusion every 3 weeks for 60 minutes.

[Precautions]
●Immune-related pneumonitis: Withhold for moderate and permanently discontinue for severe or life-threatening pneumonitis.
●Immune-related hepatitis: Monitor changes in liver function. Withhold for moderate and permanently discontinue for severe or life-threatening elevations in transaminases or total bilirubin.
● Immune-Related Colitis: Withhold for moderate or severe, and permanently discontinue for life-threatening colitis.
● Immune-Related Endocrinopathy:
o Hypophysitis: Withhold for moderate or severe, and permanently discontinue for life-threatening hypophysitis.
o Thyroid Disease: Monitor thyroid function. Withhold for symptomatic thyroid disease.
o Adrenal Insufficiency: Withhold for symptomatic adrenal insufficiency.
o Type 1 Diabetes: Withhold for Grade ≥3 hyperglycemia.
● Immune-Related Myasthenic Syndrome/Myasthenia Gravis, Guillain-Barré, or Meningoencephalitis: Permanently discontinue for any grade.
● Ocular Inflammatory Toxicity: Withhold for moderate and permanently discontinue for severe ocular Inflammatory Toxicity.
● Immune-Related Pancreatitis: Withhold for moderate or severe, and permanently discontinue for life-threatening pancreatitis, or recurrent pancreatitis of any grade.
● Infection: Withhold for severe or life-threatening infection.
●Infusion reactions: Interrupt or slow the infusion rate for mild or moderate infusion reactions and discontinue for severe or life-threatening infusion reactions.
●Embryo-fetal toxicity: TECENTRIQ may cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception.

[Adverse reactions] The most common adverse reactions (≥ 20% of patients) include: fatigue, decreased appetite, nausea, urinary tract infection, pyrexia, and constipation.

[Pregnant women use] Advise female patients that TECENTRIQ may cause fetal harm. Instruct females of reproductive potential to use effective contraception during treatment and for at least 5 months after the last dose of TECENTRIQ.

[Pediatric use] The safety and effectiveness of TECENTRIQ in pediatric patients has not been established.

[Manufacturer] Genentech, Inc.